Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Pembrolizumab (nicht kleinzelliges lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-55. [Pembrolizumab (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 459. 2016 Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Germany; Humans; State Medicine Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000133 Date abstract record published 18/01/2017 |